Verition Fund Management LLC Trims Stock Position in Catalent, Inc. (NYSE:CTLT)

Verition Fund Management LLC reduced its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 12.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 364,683 shares of the company's stock after selling 53,864 shares during the period. Verition Fund Management LLC owned about 0.20% of Catalent worth $22,089,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CTLT. Public Sector Pension Investment Board lifted its position in Catalent by 16.2% in the third quarter. Public Sector Pension Investment Board now owns 7,910 shares of the company's stock valued at $479,000 after acquiring an additional 1,100 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Catalent by 4.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,024,240 shares of the company's stock valued at $62,038,000 after acquiring an additional 45,564 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Catalent by 12.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company's stock valued at $2,301,000 after acquiring an additional 4,088 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock valued at $83,733,000 after acquiring an additional 863,624 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Catalent by 9.3% in the third quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company's stock valued at $16,185,000 after acquiring an additional 22,785 shares during the last quarter.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Robert W. Baird reissued a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. StockNews.com lowered shares of Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. Finally, William Blair restated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Stock Performance

Shares of Catalent stock traded up $0.11 on Friday, reaching $61.11. 771,192 shares of the stock were exchanged, compared to its average volume of 2,030,913. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The business has a fifty day moving average price of $59.90 and a two-hundred day moving average price of $58.47. The firm has a market capitalization of $11.09 billion, a PE ratio of -27.04, a PEG ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the firm earned ($0.10) earnings per share. The company's revenue was up 4.2% compared to the same quarter last year. As a group, research analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.